Evidence map›Paper›PMID 35634342›Full record

ReviewFrontiers in immunology2022

Helix-Loop-Helix Proteins in Adaptive Immune Development.

Megan Aubrey, Zachary J Warburg, Cornelis Murre

Abstract readReview
In one paragraph

Review in Frontiers in immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. The Function of E2A in B-Cell Development.Advances in experimental medicine and biology · 2024
    Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Megan AubreyDivision of Biological Sciences, Section of Molecular Biology, University of California, San Diego, San Diego, CA, United States.
Zachary J WarburgDivision of Biological Sciences, Section of Molecular Biology, University of California, San Diego, San Diego, CA, United States.
Cornelis MurreDivision of Biological Sciences, Section of Molecular Biology, University of California, San Diego, San Diego, CA, United States.

Funding

MOLECULAR BIOLOGICAL APPROACHES TO ENDOCRINOLOGYT32DK007541 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI GAULTON, KYLE JEFFRIE, MAJITHIA, AMIT · 1987 to 2022
$4.5M
NIDDK NIH HHS T32 DK007541
6 · The paper itself

Abstract

The E/ID protein axis is instrumental for defining the developmental progression and functions of hematopoietic cells. The E proteins are dimeric transcription factors that activate gene expression programs and coordinate changes in chromatin organization. Id proteins are antagonists of E protein activity. Relative levels of E/Id proteins are modulated throughout hematopoietic development to enable the progression of hematopoietic stem cells into multiple adaptive and innate immune lineages including natural killer cells, B cells and T cells. In early progenitors, the E proteins promote commitment to the T and B cell lineages by orchestrating lineage specific programs of gene expression and regulating VDJ recombination of antigen receptor loci. In mature B cells, the E/Id protein axis functions to promote class switch recombination and somatic hypermutation. E protein activity further regulates differentiation into distinct CD4+ and CD8+ T cells subsets and instructs mature T cell immune responses. In this review, we discuss how the E/Id proteins define the adaptive immune system lineages, focusing on their role in directing developmental gene programs.

Indexed as

Hematopoietic Stem CellsTranscription FactorsB-LymphocytesCell DifferentiationCell LineageTranscription FactorsB cell developmentE proteinshematopoiesisHLHId proteinslymphopoiesisT cell developmentVDJ recombination

Identifiers

PMID35634342
PMCPMC9134016

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.